Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

华盛顿大学参与者参与和癌症基因组测序中心 (WU-PE-CGS)

• 批准号: 10599739
• 负责人: GRAHAM A. COLDITZ
• 金额: $ 2.85万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10599739
• 关键词: Address; Advocacy; Aftercare; Age; Cancer Patient; Cancer Survivor; Capital; Cholangiocarcinoma; Colorectal Cancer; Communication; Communities; Complex; Development; Disadvantaged; Discipline; Ensure; Environment; Evaluation Research; Family; Fostering; Genomics; Goals; Health Benefit; Health system; Investments; Knowledge; Lead; Leadership; Malignant Neoplasms; Methodology; Multiple Myeloma; Participant; Patient advocacy; Patients; Persons; Population; Provider; Research; Research Personnel; Resources; Rural Population; Science; Technology; Underserved Population; Universities; Vision; Washington; anticancer research; cancer genomics; cancer health disparity; career; evidence base; genome sequencing; improved; innovation; interdisciplinary collaboration; member; outreach; patient engagement; patient oriented; patient population; rare cancer; recruit; success; synergism

PROJECT SUMMARY Vision. Participant engagement and sequencing research from the Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) will fill critical gaps in knowledge, methodology, and characterization of understudied cancer populations, leading to optimal approaches to participant engagement, outreach, and communication in genomic characterization studies. Goal. The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research. Our focus is on rare and understudied cancer populations with significant disparities including cholangiocarcinoma, multiple myeloma, and colorectal cancer under age 50. Participant engagement strategies are most effective when they are adapted and implemented in real-world settings in partnership with community and patient advocacy stakeholders. Setting. Our Center will be housed in an exceptional environment that fosters transdisciplinary collaboration, catalyzes new ideas in patient engagement, and ensures support for patient engagement and genome sequencing that finds solutions for complex recruitment and engagement challenges in real-world settings with underrepresented patient populations. Significant matching contributions from Washington University will allow us to quickly and strategically invest in ideas. Aims. The specific aims of the Center are to: (1) Advance the field of participant engagement to study cancer disparities and rare cancers by conducting innovative and impactful direct stakeholder engagement with continuous evaluation and research; (2) Expand an exceptional, diverse team of investigators, patients, and advocacy stakeholders; (3) Address cancer disparities by understanding barriers to and improving the ability for disadvantaged and understudied populations to encounter, use, and benefit from genomic sequencing and analysis; (4) Organize and integrate Center units to facilitate transdisciplinary, team science within our Center and across the PE-CGS Network. Innovations and impact. The WU-PE-CGS builds on a long and outstanding record of leadership in both cancer disparities and genomic research across the cancer continuum. We will be particularly innovative and allow for a significant return on the scientific investment in several ways. First, our Center has distinctive features that include a combined focus on cancer disparities, the application of strategies to increase participant engagement in research, success in biospecimen acquisition, and exceptional genomic sequencing expertise. Second, we have assembled a diverse, world class team with strong linkages to multiple rare and understudied cancers. Third, we engage investigators from different disciplines and invest in the development of early career scholars. Fourth, we will strategically and creatively disseminate products in ways that will benefit researchers, practitioners, and community members. Fifth, we will partner with exceptional patient-centered and wide-reaching advocacy groups to engage patients, optimize recruitment, and seamlessly return results. Input from these groups, patients, and their families is a key strength that will leverage our track record of stakeholder-engaged research. And finally, we have developed a focused strategy for collective integration of our units. These synergies will allow our Center to become a national resource for optimal approaches to participant engagement, outreach, and communication in genomic characterization studies and other studies as technologies advance that will accelerate progress for both the scientific community, patients and their communities. In summary, we are uniquely situated to advance a network of participant engagement and sequencing researchers, integrate research with patients and their stakeholders, build intellectual capital, and significantly enhance the capacity for participant engagement and genomic characterization studies. This Center will ultimately benefit health systems, providers, and people with rare cancers and lead to a reduction in cancer disparities.

项目摘要 视野来自华盛顿大学参与者的参与和排序研究 参与和癌症基因组测序中心（WU-PE-CGS）将填补知识的关键空白， 方法学，并对研究不足的癌症人群进行表征，从而找到最佳方法， 参与者参与，推广和基因组表征研究的沟通。 目标. WU-PE-CGS的总体目标是建立一个严格的，科学的证据基础， 癌症患者和治疗后癌症幸存者参与癌症研究。我们 重点是具有显著差异的罕见和未充分研究的癌症人群，包括胆管癌， 多发性骨髓瘤和结直肠癌参与者参与策略最有效 当它们与社区和患者合作在现实世界中进行调整和实施时， 利益攸关方的倡导。 设置.我们的中心将被安置在一个特殊的环境，促进跨学科的合作， 促进患者参与的新思路，并确保对患者参与和基因组的支持 排序，为现实环境中复杂的招聘和参与挑战找到解决方案， 代表性不足的患者群体。来自华盛顿大学的重要配套捐款将使 我们可以快速地、战略性地投资于创意。 目标。本中心的具体目标是：（1）促进参与者参与癌症研究的领域 通过开展创新和有影响力的直接利益相关者参与， 持续的评估和研究;（2）扩大一个特殊的，多样化的研究人员，患者和 倡导利益相关者;（3）通过了解障碍和提高能力来解决癌症差异 让弱势群体和研究不足的人群接触、使用和受益于基因组测序， 分析;（4）组织和整合中心单位，以促进我们中心内的跨学科，团队科学 和整个PE-CGS网络。 创新和影响。在WU-PE-CGS建立在长期和杰出的领导记录，在两个癌症 差异和基因组研究在整个癌症连续体。我们将特别创新，并允许 在几个方面为科学投资带来了可观的回报。首先，我们的中心具有鲜明的特色， 包括对癌症差异的综合关注， 参与研究、成功获取生物标本以及卓越的基因组测序专业知识。 第二，我们组建了一支多元化的世界级团队，与多个稀有和未充分研究的 癌的第三，我们聘请来自不同学科的调查人员，并投资于早期开发 职业学者第四，我们将以有益的方式战略性和创造性地传播产品 研究人员、从业人员和社区成员。第五，我们将与卓越的以患者为中心的 和广泛的倡导团体，以吸引患者，优化招聘，并无缝返回结果。 来自这些团体、患者及其家属的意见是一个关键的力量，将利用我们的跟踪记录， 企业家参与的研究。最后，我们制定了一项有重点的战略， 我们的单位。这些协同作用将使我们的中心成为一个国家资源， 参与者在基因组表征研究和其他研究中的参与、外联和沟通 随着技术的进步，这将加速科学界、患者及其家属的进步。 社区. 总之，我们在推进参与者参与和排序网络方面具有独特的优势 研究人员，将研究与患者及其利益相关者结合起来，建立智力资本， 提高参与者参与和基因组特征研究的能力。这个中心将 最终使卫生系统、提供者和罕见癌症患者受益，并减少癌症发病率。 差距。